Obseva SA : Wired News – ObsEva Released Positive Top Line Results From IMPLANT2 Phase 3 Clinical Trial Evaluating Nolasiban In IVF

About Assisted Reproductive Technology

Assisted reproductive technology (ART) is the technology used to achieve pregnancy in procedures such as fertility medication, in vitro fertilization, and surrogacy. It is reproductive technology used primarily for infertility treatments. It mainly belongs to the field of reproductive endocrinology and infertility and may also include intracytoplasmic sperm injection (ICSI) and cryopreservation. Some forms of ART are also used with regard to fertile couples for genetic reasons. While the success of ART depends on multiple factors such as embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation.

About ObsEva S.A.

Founded in 2012 and headquartered in Switzerland, ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy.

Stock Performance Snapshot

February 27, 2018 - At Tuesday's closing bell, ObsEva's stock was slightly up 0.76%, ending the trading session at $14.61.

Volume traded for the day: 49.61 thousand shares, which was above the 3-month average volume of 35.63 thousand shares.

Stock performance in the last month – up 35.28%; previous three-month period – up 46.25%; past twelve-month period – up 4.43%; and year-to-date - up 49.69%

After yesterday's close, ObsEva's market cap was at $509.74 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors

:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly.

If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number:

73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Source : https://finance.yahoo.com/news/wired-news-obseva-released-positive-120000307.html

1892
Obseva SA : Wired News – ObsEva Released Positive Top Line Results From IMPLANT2 Phase 3 Clinical Trial Evaluating Nolasiban In IVF

Source:Yahoo Finance

Obseva SA : Wired News – ObsEva Released Positive Top Line Results From IMPLANT2 Phase 3 Clinical Trial Evaluating Nolasiban In IVF

Obseva SA : Wired News – ObsEva Released Positive Top Line Results From IMPLANT2 Phase 3 Clinical Trial Evaluating Nolasiban In IVF

Source:4-Traders

Obseva SA : Wired News – ObsEva Released Positive Top Line Results From IMPLANT2 Phase 3 Clinical Trial Evaluating Nolasiban In IVF